Chronic myelocytic leukemia (CML) affects
adult population between the ages of 40 and 60 and is uncommon in children
younger than 10 years. CML is detected based on a simple blood test that
exhibits an abnormally high count of white blood cells. Chronic myelocytic
leukemia is usually a rearrangement of two particular chromosomes known as
Philadelphia chromosome, which produces an abnormal enzyme (tyrosine kinase)
that is responsible for the abnormal growth pattern of the white blood cells in
a human body. In Chronic myelocytic leukemia, most of the leukemia cells are produced
in the bone marrow. Few leukemia cells are also produced in the spleen and
liver. Chronic stage of myelocytic leukemia is characterized by the increases
in the number of white blood cells or leukemia cells that fill the bone marrow
and enter the human bloodstream.
Chronic myeloid leukemia (CML) is also known
as chronic myelogenous leukemia. It is a type of cancer that starts in the
blood-forming cells of the human bone marrow and invades the blood. The
leukemia cells undergo numerous changes as the disease progresses and
inevitable to blast crisis. Massive enlargement of the spleen, fever and weight
loss is the common symptom in blast crisis. Initially, CML affected patient
become fatigued, weak, lose their appetite, reduce weight, develop a fever or
night sweats, and notice a sensation of being full due to enlarged spleen. As
CML progresses to blast crisis, the patient becomes sicker due to the decrease
in number of red blood cells and platelets causing paleness, bruising, and
bleeding. Various treatments available for CML are radiation therapy, blood
cell transplantation and chemotherapy.
The leading competitors in Chronic Myelocytic
Leukemia (CML) therapeutics market are AbbVie Inc, Altor BioScience Corp,
arGEN-X BV, Array BioPharma Inc, Ascentage Pharma Group Corp Ltd, Atara
Biotherapeutics Inc, Bayer AG, Bio-Path Holdings Inc, BioLineRx Ltd, BioSight
Ltd, Boston Biomedical Inc and others. Geographically, the Chronic Myelocytic
Leukemia (CML) therapeutics market is spread across Asia, Africa, Americas,
Europe, Middle East and rest of the world.
According to the study “Chronic
Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2018”,
the latest guide for Chronic Myelocytic Leukemia provides comprehensive
information on the therapeutics under development for Chronic Myelocytic
Leukemia (Oncology), drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type involved for CML. It also describes the
descriptive pharmacological action of the CML therapeutics, complete research,
development history, latest news and press related reports. The guide is
developed using data and information obtained from various researcher's
proprietary databases, company, university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press related
reports. The most recent developments in Chronic Myelocytic Leukemia (CML) are
captured and recorded on a real time basis.
Advanced medical technology has witnessed
great changes in the field of Chronic Myelocytic Leukemia (CML) diagnostics
that strengthens the performance of drug manufacturers globally. It was
observed that Chronic Myelocytic Leukemia (CML) is undergoing a tremendous
research in the area of therapeutics and drug administration. This growth is
expected to continue at a moderate pace over the next few years.
To know,
more click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204